Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Anti-BCMA-CAR-T-Cell-Therapy-Juno-Therapeutics (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 03 Dec 2018 According to a Celgene Corporation media release, Interim results were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
    • 03 Dec 2018 Interim results (N=44) presented in a Celgene Corporation Media Release.
    • 25 Oct 2018 According to a Celgene Corporation media release, data from the study will be presented at the 2018 American Society of Hematology (ASH) annual meeting in December.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top